C. difficile 위험도


HAP, complicated SSTIVancomycin-resistant E. faecium infectionUncomplicated SSTI600 mg IV/PO q12h x10-14d600 mg IV/PO q12h x14-28d400 mg PO q12h x10-14d

HAP, complicated SSTIVancomycin-resistant E. faecium infectionUncomplicated SSTI10 mg/kg IV/PO q8h x10-14d10 mg/kg IV/PO q8h x14-28d- Age <5y 10 mg/kg PO q8h x10-14d

  • Age 5-11y 10 mg/kg PO q12h x10-14d

  • Age ≥12y 600 mg PO q12h x10-14d

Mild or moderate hepatic impairmentSevere hepatic impairmentNo dose adjustmentNo data

No dosage adjustment

If HD begins within 3h after Linezolid dose: Additional 30% recommended dose IV/PO after HD

General Information

Targeted or empiric therapy for gram positive infections including skin and soft tissue, and pneumonia.

Covers MRSA and VRE.

Monitor CBC weekly; blood pressure; signs and symptoms of serotonin syndrome.

Perform visual function tests for therapy >3 months or if symptoms develop during therapy.


  • Diarrhea

  • Nausea

  • Vomiting

  • Headache


  • Lactic acidosis

  • Clostridioides difficile infection

  • Myelosuppression

  • Injury of liver

  • Peripheral neuropathy

  • Seizure

  • Optic nerve disorder

  • Serotonin syndrome

  • SSRI and other serotonergics/MAOIs: increased risk of serotonin syndrome

  • Rifampin: decreases linezolid levels

Antimicrobial class: Oxazolidinone

Pregnancy category: C

Average serum half life: 5 hours

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic


  • Use not recommended unless patients monitored for potential blood pressure increases.

  • Use not recommended in patients with CNS infections or catheter-related bloodstream infections/catheter-site infections.

  • Monitoring recommended for ophthalmic changes.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.